Third Circuit: Samsung Bioepis's Remicade Biosimilar Does Not Infringe J&J Patents
Third Circuit · 2026-04-14 · Defendant Win · Impact: 75/100
Johnson & Johnson v. Samsung Bioepis Co Ltd, decided by Third Circuit on April 14, 2026, resulted in a defendant win outcome. The Third Circuit affirmed the District of Delaware's decision, holding th...
CA3 Affirms Enbrel Patent Infringement, Reverses Willfulness Finding
Third Circuit · 2025-06-05 · Mixed · Impact: 60/100
Amgen Inc v. Celltrion USA Inc, decided by Third Circuit on June 5, 2025, resulted in a mixed outcome. The Third Circuit affirmed the District Court's finding of infringement of Amgen's patents for it...